Diagnosis for Neonatal Sepsis-Associated Encephalopathy: Don't Forget Neuropathological Biomarkers

Neonatal sepsis-associated encephalopathy (nSAE) poses significant diagnostic challenges due to nonspecific clinical manifestations and limitations of current diagnostic standards. It is imperative to conduct extensive research to elucidate the intricate relationship between neuropathological biomarkers and neonatal sepsis, which represents an intriguing and significant subject for exploration. This article emphasizes the critical need to integrate neuropathological biomarkers, such as neuron-specific enolase (NSE), S100β, glial fibrillary acidic protein (GFAP), Tau, and ubiquitin C-terminal hydrolase L1 (UCH-L1), into diagnostic protocols to improve early detection, prognostication, and personalized management of nSAE.

A narrative synthesis of existing literature and clinical studies was conducted, focusing on the role of neuropathological biomarkers in nSAE. Key studies evaluating serum and cerebrospinal fluid levels of NSE, S100β, GFAP, Tau, and UCH-L1 were analyzed. Mechanistic pathways, temporal biomarker patterns, and comparative analyses with inflammatory/metabolic biomarkers were reviewed to assess diagnostic and prognostic utility.

Elevated levels of neuropathological biomarkers, particularly NSE and S100β, were strongly associated with neuronal and glial injury in nSAE. These biomarkers correlated with adverse outcomes, including cognitive impairment and developmental delays. For example, NSE levels reflected hypoxia-induced neuronal damage, while S100β indicated astrocytic activation and severity of brain injury. Tau and UCH-L1 demonstrated potential for tracking neurodegeneration, and GFAP highlighted astrocytic reactivity. However, no universally accepted diagnostic criteria or validated biomarker thresholds exist for neonates, contrasting with adult sepsis-associated encephalopathy.

Neuropathological biomarkers offer promising tools for stratifying nSAE severity, guiding neuroprotective interventions, and improving prognostication. Future research must prioritize large-scale clinical validation, mechanistic studies, and comparative analyses with other biomarker categories to establish standardized protocols. Integrating these biomarkers into neonatal care could enhance early diagnosis, inform targeted therapies, and mitigate long-term neurological morbidity. Addressing these gaps is critical for advancing precision medicine in neonatal sepsis management.